Vol. 6 No. 11 (2026): November
Health Technology Reviews

ALS in Focus: Canada’s Systems for ALS Care and Support

decorative image of the issue cover

Published November 16, 2026

Key Messages

What Is the Issue?

  • Amyotrophic lateral sclerosis (ALS) is a rare, progressive, nervous system disease that causes loss of movement, functional impairment, and eventual paralysis requiring continuous care for daily activities and functions such as breathing and eating. There is no cure, and 80% of people with ALS die within 5 years of diagnosis.
  • ALS creates challenges and significantly impacts individuals, families, caregivers, and health systems in Canada due to its complex and evolving diagnostic and care pathways, high mortality burden, and reliance on coordinated multidisciplinary care. There is also variability in the organization and funding of ALS services across provinces and territories, alongside differences in access to timely diagnosis, treatment, and supportive care.
  • This report provides a pan-Canadian overview of ALS care pathways and experiences, including diagnosis, treatment, supportive care, and ethical considerations. Federal, provincial, and territorial health system decision-makers can use this report to understand what areas of ALS care require further attention or resources, and to collaborate on health system planning and resource allocation.

What Did We Do?

  • We conducted a scan of the ALS literature to understand the clinical pathway (i.e., diagnosis, treatment, and supportive care for people living with ALS) and ethical considerations that may arise from how ALS care and support are organized and coordinated across Canada.
  • We supplemented this information with real-world health care administrative data, registry data, and public and private drug claims and drug cost data. We also engaged with people living with ALS, caregivers, ALS clinic coordinators, and representatives from ALS societies across Canada.
  • We formed an advisory group (the ALS in Focus Advisory Group) to inform and review our work. The group included people living with ALS, caregivers, physicians specializing in the management and treatment of ALS, an ALS clinic coordinator and nurse, a clinical ethicist, and leaders from provincial ministries of health responsible for health system planning and service delivery.

What Did We Find?

  • The ALS care pathway in Canada involves a complicated and lengthy diagnostic process, few disease-modifying drugs, and a complex array of health care and support services (e.g., multidisciplinary care provided at specialized ALS clinics, community-based home care services, and ALS societies). There is also wide variability in access to the full spectrum of services available across jurisdictions, making it challenging to navigate for people living with ALS and caregivers.
  • Registry data from 7 provinces indicate that the average time to receive an ALS diagnosis is 15 months, and that it is longer for those in rural communities. Time to diagnosis is an important metric in ALS care, as a delayed diagnosis may impact eligibility for some disease-modifying drugs and may result in delayed access to multidisciplinary care for people living with ALS.
  • In Canada, there are currently 3 disease-modifying drugs used to treat ALS: riluzole, edaravone, and tofersen. All public drug plans provide coverage for riluzole, and most provide coverage for edaravone. At the time of report publication, tofersen is under negotiation with the pan-Canadian Pharmaceutical Alliance (pCPA) and is not yet covered by any public drug plans. Tofersen is used to treat a specific subtype of ALS (SOD1 ALS), which makes up approximately 2% of people living with ALS worldwide.
  • Drug claims data for 10 provinces and territories indicate that the use of disease-modifying drugs for ALS increased over the past 6 years. Data also indicate both an increased number of people receiving ALS drugs from public plans and a rising share of drug costs covered by public plans.
  • Some people living with ALS have difficulties covering the costs of drugs, devices, and other supportive care that may not be fully covered by public plans. They may also experience challenges related to accessing certain therapies and navigating various health systems to receive health care.
  • Disparities in the ALS care experience for people living with ALS across Canada can be exacerbated for those with limited financial means and for those in rural or remote locations. Engagement activities with a First Nations and Métis couple reiterated long-standing challenges of systemic discrimination experienced by Indigenous Peoples in Canada that can be intensified in the context of ALS care.

What Does This Mean?

  • Opportunities for improving care for people living with ALS in Canada may exist around reducing diagnostic and treatment delays, increasing access to supportive therapies, and improving coordination between different parts of health care systems.
  • Health system decision-makers can consider where attention or resources are needed for improving:
    • timely diagnosis and referral to an ALS clinic
    • equitable access to genetic testing and counselling
    • access to supportive therapies (including access to ALS clinics, multidisciplinary care, and services from ALS societies)
    • coordination and standardization between different parts of health care systems (e.g., to address ALS and non-ALS symptoms and to improve capacity for long-term care homes to accommodate advanced respiratory and feeding needs)
    • supports for caregivers (e.g., health care system navigation, mental health, respite, and medical and home care supports)
    • health system data to better understand challenges in ALS diagnosis, access, and care.
  • Health system decision-makers can consider options for reducing disparities for people living with ALS who are also part of equity-deserving groups, including:
    • those living in rural and remote areas who have difficulty accessing care or cannot get care at all
    • those who do not have the financial or job stability to afford the many out-of-pocket costs required to maintain quality of life
    • those who do not have caregivers to support them physically, medically, and emotionally
    • Indigenous individuals who have described the importance of training health care professionals in culturally safe care.